Study guide

3.3 Sample Types, Clinical Context & Predictive Metrics

Certified Genetic Counselor CGC

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics

2 Domain 1A: Clinical Information

1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review

3 Domain 1B: Human Development

1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development

4 Domain 1C: Chromosomal & Contiguous Gene Syndromes

1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)

5 Domain 1C: Hereditary Cancer Syndromes

1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition

6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions

1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework

7 Domain 2A: Pedigree & Risk Assessment

2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans

8 Domain 2B: Inheritance Principles

2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype

9 Domain 2B: Population Genetics & Variation

2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility

10 Domain 3A: Test Methodologies

3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics

11 Domain 3A: Variant Interpretation

3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework

12 Domain 3B: Testing Options

3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing

13 Domain 3C: Reproductive Risk Management

3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)

14 Domain 4A: Counseling Foundations

4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility

15 Domain 4A: Theories, Coping & Dynamics

4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics

16 Domain 4B: Communication & Education

4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making

17 Domain 5A–B: Finance & Client Resources

5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery

18 Domain 5C: Legal & Regulatory Requirements

5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing

19 Domain 5D: Professional Frameworks

5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education

20 Integration & Exam Strategy

6.1 Integrating Domains in Case-Based Practice & Exam Strategy

3.3 Sample Types, Clinical Context & Predictive Metrics

Key Takeaways Explain This Topic AI

Sample type (blood, saliva/buccal, cultured cells, tissue, CVS, amniocytes) affects DNA quality, culture success, mosaicism representation, and which cytogenetic vs molecular assays are feasible.

Sensitivity and specificity describe intrinsic test performance; PPV and NPV additionally depend on pretest probability (prevalence or clinical prior).

Analytic validity, clinical validity, and clinical utility are distinct layers—passing lab QC does not automatically mean the result improves patient outcomes.

High sensitivity is necessary but not sufficient for population screening; PPV collapses when prevalence is low even if specificity looks “high.”

Counseling must translate metrics into decisions: what a negative result rules out, what residual risk remains, and whether the sample can even support the ordered test.

Last updated: August 2026

Clinical context drives both sample and metric interpretation

A perfect assay on the wrong specimen—or a highly sensitive screen in a low-prevalence population—still produces counseling failures. Domain 3A links test methodologies to sample type , clinical context , and predictive value . You must know what each specimen can support and how to move fluently among sensitivity, specificity, PPV, NPV, and the validity/utility triad.

Sample types and practical considerations

Sample Typical uses Counsel / logistics notes

Peripheral blood Karyotype, CMA, most molecular sequencing Standard for constitutional testing; reflects leukocyte lineage—may miss tissue-limited mosaicism

Saliva / buccal Many molecular assays Convenient; DNA yield/quality variable; eating, smoking, bacterial DNA can affect QC; confirm lab acceptance

Cultured fibroblasts / other tissue Suspected mosaicism; culture-dependent cytogenetics Invasive relative to blood; chosen when blood may not represent the relevant tissue

CVS (chorionic villi) Prenatal diagnosis Placental lineage; mosaicism/CPM issues detailed in prenatal chapters—flag that placenta ≠ always fetus

Amniotic fluid / amniocytes Prenatal diagnosis Fetal cell source after culture or direct methods; procedure-risk counseling is separate from lab methodology

Products of conception / fetal tissue Pregnancy loss workup Tissue quality and maternal cell contamination matter for interpretation

Tumor / somatic tissue Somatic variant profiling Not a substitute for germline testing; germline confirmation may need blood/saliva

Sample–method matching traps

Ordering a karyotype when only saliva DNA was collected without confirming the lab can culture or whether a DNA-based alternative is intended.

Interpreting a normal blood genetic test as excluding mosaic disease confined to other tissues.

Treating CVS results as identical to amniocentesis without acknowledging placental mosaicism risk (full CPM algorithms belong in prenatal diagnostic content).

Using tumor NGS reports as definitive germline results without orthogonal germline specimen testing when hereditary risk is in question.

Preanalytical realities worth saying out loud

Ship time, heparin vs EDTA tubes for different assays, maternal cell contamination in prenatal samples, and failed cultures all change turnaround and sometimes force a redraw. Pretest counseling should include the possibility of quantity/quality insufficient (QNS) results.

Sensitivity, specificity, PPV, and NPV

Memorize definitions, then practice how prevalence moves predictive values.

Metric Definition Formula intuition

Sensitivity Among people with the condition (or target variant/class), the proportion who test positive True positives / (true positives + false negatives)

Specificity Among people without the condition, the proportion who test negative True negatives / (true negatives + false positives)

Positive predictive value (PPV) Among people who test positive , the proportion who truly have the condition True positives / (true positives + false positives)

Negative predictive value (NPV) Among people who test negative , the proportion who truly do not have the condition True negatives / (true negatives + false negatives)

The prevalence dependence rule

Sensitivity and specificity are properties of the test in a defined comparison (with caveats about spectrum bias). PPV and NPV depend on pretest probability (disease prevalence in the tested population or individualized clinical prior).

  • If prevalence falls… What happens
  • Same sensitivity & specificity PPV decreases (more of the positives are false positives)
  • Same sensitivity & specificity NPV increases (negatives are more likely truly negative)

This is why a screening test with 99% specificity can still yield a modest PPV in a rare condition: false positives from the huge unaffected population can outnumber true positives.

Worked conceptual example (screening intuition)

Imagine a condition with prevalence 1/1,000 in a screened population and a test with 99% sensitivity and 99% specificity .

In 100,000 people: ~100 affected; ~99 true positives; ~1 false negative.

~99,900 unaffected; at 99% specificity → ~999 false positives.

PPV ≈ 99 / (99 + 999) ≈ 9% .

Families hear “99% accurate” and imagine a 99% PPV. Your counseling job is to separate sensitivity/specificity language from predictive value after a positive screen , then offer diagnostic confirmation pathways.

Diagnostic vs screening context

Context Prior Metric emphasis

High-suspicion diagnostic testing High pretest probability NPV of a negative may still leave residual risk if sensitivity <100%; PPV of a well-targeted test is often higher

Population screening Low prevalence Even excellent specificity can yield limited PPV; confirm positives

Cascade testing for a known familial variant Prior depends on relatedness/Mendelian risk Site-specific testing performance differs from population screens

Analytic validity, clinical validity, clinical utility

These three layers appear throughout genetic testing policy and Domain 3A reasoning:

Layer Question it answers Example

Analytic validity Does the lab assay accurately and reliably detect the analyte/variant it claims to detect? Does the NGS pipeline call this SNV with confirmed accuracy and reproducibility?

Clinical validity How well does the test result relate to the presence/absence/risk of the clinical phenotype or disease? Does a pathogenic variant in this gene actually associate with the syndrome with known penetrance?

Clinical utility Does using the test improve outcomes, decisions, or care meaningfully (diagnosis, management, prevention, reproductive options)? Does identifying the variant change surveillance, therapy eligibility, or reproductive planning?

Exam-ready distinctions:

A test can be analytically valid yet have weak clinical validity if the gene–disease relationship is uncertain (interpretation problem).

A result can be clinically valid yet have limited clinical utility today if no management change or decision follows (still may have personal utility for some patients—counsel explicitly).

VUS results often reflect limited clinical validity for that specific variant even when the assay analytically sequenced the base correctly.

Putting sample, method, and metrics together

Confirm the specimen can support the method (culture vs DNA; prenatal source limitations).

State what positive and negative mean using sensitivity/specificity, then translate to PPV/NPV using the patient’s pretest probability.

Avoid promising “ruled out” when sensitivity is incomplete or the sample might not represent mosaic tissue.

Separate lab accuracy ( analytic validity ) from disease meaning ( clinical validity ) and actionability ( clinical utility ).

For screens, plan the confirmatory diagnostic step before disclosing a low-PPV positive as if it were a diagnosis.

Mastering this section prevents the most common Domain 3 counseling error: treating every laboratory adjective—“sensitive,” “comprehensive,” “normal”—as if it carried the same predictive meaning in every clinical context.